Privately held Proteona announces that Twist Bioscience (TWST +0.4%) has joined an
international alliance led by Proteona aimed at developing neutralizing
antibody therapies against COVID-19 for vulnerable immunocompromised
patients.
Twist has developed a highly parallel
silicon-based DNA synthesis platform that enables the manufacture of
millions of “oligos” of different lengths with a high degree of accuracy
that can be used to optimize therapeutic IgG antibodies.
Proteona has developed single-cell proteogenomics technology
that enables the simultaneous screening of antibodies targeting
multiple viral variants. In COVID-19, it is analyzing blood samples from
recovered patients and screening for B cells that produce neutralizing
antibodies against SARS-CoV-2. Identified candidates will be optimized
for possible therapeutic use.
https://seekingalpha.com/news/3579102-twist-bio-joins-covidminus-19-therapy-development-alliance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.